425: Iris Acquisition Corp. Amends Business Combination Agreement with Liminatus Pharma, Reducing Enterprise Value

Iris Acquisition Corp. and Liminatus Pharma have amended their business combination agreement for the sixth time, significantly reducing the enterprise value of Liminatus to $175 million.

Summary

• Iris Acquisition Corp. has filed an 8-K report detailing the sixth amendment to its business combination agreement (BCA) with Liminatus Pharma.
• The primary change is a reduction in the enterprise value associated with Liminatus to $175 million.
• The filing also includes a fifth amendment to the Equity PIPE Subscription Agreement, reducing the Aggregate Purchase Price to $15 million and the number of subscribed shares to 1,500,000.
• The amendments address definitions, conditions to obligations, intellectual property, listing requirements, and payments to sponsors.
• The document outlines the specifics of the amendments to the Business Combination Agreement and the PIPE Equity Subscription Agreement.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the repeated amendments, reduced valuation, and extended timelines, suggesting potential challenges in completing the deal. However, the continued efforts to finalize the transaction offer some hope.

Positives

• The continued amendments suggest ongoing efforts to finalize the business combination.
• The reduction in enterprise value might make the deal more attractive to investors.
• The PIPE Equity Subscription Agreement has been amended to $15 million.

Negatives

• The repeated amendments to the BCA and Subscription Agreement may indicate underlying issues or challenges in completing the transaction.
• The significant reduction in enterprise value for Liminatus Pharma could reflect a less favorable assessment of its prospects.
• SPAC Operating Expenses are capped at $5,000,000.

Risks

• The deal may still face challenges in closing, given the history of amendments and extensions.
• The reduced enterprise value could impact investor confidence and the ultimate success of the combined entity.
• Failure to maintain the listing of publicly traded Equity Securities of SPAC on a nationally recognized medium of no less significance than the OTC Pink Market or any national securities exchange acceptable to the Company could lead to termination of the agreement.

Future Outlook

The document does not provide specific forward-looking statements beyond the intention to list on NASDAQ only the ParentCo Common Stock and the ParentCo Public Warrants after the Closing.

Industry Context

SPAC mergers have faced increased scrutiny and market volatility, leading to renegotiations and deal terminations. This amendment reflects a trend of SPACs adjusting valuations to reflect current market conditions.

Comparison to Industry Standards

• SPAC deals often involve renegotiations, especially in the biotech sector, where clinical trial outcomes and regulatory approvals can significantly impact valuations.
• Comparable companies that have undergone similar SPAC transactions include those that have had to adjust their deal terms due to market conditions or company performance.
• The reduction in enterprise value is not uncommon in the current SPAC market, as investors demand more favorable terms.

Stakeholder Impact

• Shareholders of Iris Acquisition Corp. will be affected by the reduced valuation and potential dilution from the PIPE financing.
• Employees of Liminatus Pharma may experience uncertainty during the merger process.
• The success of the combined entity will impact the value of the shares and the long-term prospects of the company.

Next Steps

• SPAC must maintain its listing on a recognized exchange.
• Parties must work towards satisfying the remaining conditions for closing the business combination.
• The parties intend to list on NASDAQ only the ParentCo Common Stock and the ParentCo Public Warrants after the Closing.

Key Dates